Correlation Between Concentrations of Melatonin in Saliva and Serum in Patients With Delayed Sleep Phase Syndrome

Nagtegaal, J.E.; Peeters, Annelies; Swart, A.C.W.; Smits, M.G.; Kerkhof, G.A.; Meer, Y. G. Van Der

doi:10.1097/00007691-199804000-00008

Cited by 77 publications

(53 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results demonstrate a blockage in both diurnal and nocturnal production of melatonin in CRF, which generates a lack of rhythmicity in the content of this hormone. The salivary melatonin content of the control group at night during the beginning of sleep was 5.9 pg/ml, which is in agreement with previous studies that reported a normal salivary melatonin content of 4 pg/ml for this period [25]. When salivary Fig.…”

Section: Discussionsupporting

confidence: 91%

Analyses of melatonin, cytokines, and sleep in chronic renal failure

2015

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Analyses of melatonin, cytokines, and sleep in chronic renal failure

2015

View full text Add to dashboard Cite

show abstract

“…In these, melatonin output is normal but not synchronized with the external day-night variations [26]. The temperature-lowering effects of melatonin seem to occur later than sleep induction and may therefore not be the cause for the sleeppromoting effects of melatonin [27].…”

Section: Introductionmentioning

confidence: 95%

The Use of Melatonin for the Treatment of Insomnia

Zisapel¹

1999

Neurosignals

View full text Add to dashboard Cite

The pineal product melatonin is involved in the regulation of the sleep/wake cycle in humans. In blind individuals and in people travelling through time zones, melatonin rhythms are sometimes unsynchronized with the diel cycle, and nocturnal sleep may be disturbed. Low or distorted melatonin rhythms have repeatedly been reported in middle aged and elderly insomniacs. Melatonin administration effectively synchronized the sleep wake cycle in blind individuals and in subjects suffering from jet lag and advanced sleep onset in subjects suffering from delayed sleep phase syndrome. In elderly insomniacs, melatonin replacement therapy significantly decreased sleep latency, and/or increased sleep efficiency and decreased wake time after sleep onset. In addition, melatonin substitution facilitated benzodiazepine discontinuation in chronic users. These data show an association between melatonin rhythm disturbances and difficulties to promote or maintain sleep at night. Specific melatonin formulations may be useful to treat circadian-rhythm-related sleep disorders and age-related insomnia.

show abstract

“…4 These effects are distinct from those that result from the introduction of supraphysiological amounts of melatonin from exogenous sources, some of which are not receptor-mediated and involve metabolism, either in terms of formation of new bioactive compounds or interactions with free radicals. 1,2 Melatonin has been used successfully in the treatment of insomnia in older individuals, [5][6][7] in circadian rhythm sleep disorders-in particular, delayed sleep phase syndrome [8][9][10] -and in sleep disorders in children with various neurologic diseases. [11][12][13] Studies of the effects of melatonin on decreasing sleep latency and on total sleep have not always produced consistent results, however, with some investigators reporting an absence of effects.…”

Section: Introductionmentioning

confidence: 99%

Drug Insight: the use of melatonergic agonists for the treatment of insomnia—focus on ramelteon

et al. 2007

View full text Add to dashboard Cite

Melatonin, a chronobiotic that participates in the control of the circadian system, is known for its sleep-promoting effects, which include shortening of sleep latency and lengthening of sleep duration. As a result of its short half-life, melatonin does not exhibit undesirable side effects, and its broad applicability for a variety of sleep problems has been the focus of numerous scientific studies. Melatonin has not, however, received regulatory approval from the US FDA as a drug, because it can be sold freely as a food supplement. Consequently, there has been an active search for patentable melatonin receptor ligands in recent years. Ramelteon, an agonist that acts solely on melatonin MT(1) and MT(2) receptors, is of particular interest, and preliminary research indicates that it holds considerable promise for clinical applications. Ramelteon has been shown to induce sleep initiation and maintenance in various animal models and in clinical trials. In chronic insomnia, ramelteon decreases sleep latency and increases total sleep time and sleep efficiency, without causing hangover, addiction or withdrawal effects. Ramelteon is thought to promote sleep by influencing homeostatic sleep signaling mediated by the suprachiasmatic nucleus. Although ramelteon's metabolism and pharmacokinetics differ from those of melatonin, its safety seems to be sufficient for short-term application. Its long-term effects remain to be determined.

show abstract

Correlation Between Concentrations of Melatonin in Saliva and Serum in Patients With Delayed Sleep Phase Syndrome

Cited by 77 publications

References 3 publications

Analyses of melatonin, cytokines, and sleep in chronic renal failure

Analyses of melatonin, cytokines, and sleep in chronic renal failure

The Use of Melatonin for the Treatment of Insomnia

Drug Insight: the use of melatonergic agonists for the treatment of insomnia—focus on ramelteon

Contact Info

Product

Resources

About